Overview

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Status:
Not yet recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The Single-arm, multicenter study evaluate the safety and efficacy of Anlotinib Hydrochloride combined with EGFR TKIs in treating Advanced NSCLC With acquired Resistance to EGFR TKIs

Phase:

N/A

Details

Lead Sponsor:

Guangdong Association of Clinical Trials

Collaborator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Treatments:

Erlotinib Hydrochloride
Gefitinib